{"id":"W4401515835","doi":"10.1038/s41391-024-00865-5","title":"Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study","year":2024,"lang":"en","type":"article","venue":"Prostate Cancer and Prostatic Diseases","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"ca_institutions":"Jewish General Hospital; Université Laval","funders":"Medical Research Council","keywords":"Enzalutamide; Medicine; Prostate cancer; Pembrolizumab; Clinical endpoint; Internal medicine; Cohort; Oncology; Response Evaluation Criteria in Solid Tumors; Cancer; Phases of clinical research; Urology; Surgery; Clinical trial; Immunotherapy; Androgen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001897081,0.00141262,0.001958686,0.0004036435,0.0005064283,0.001275194,0.0009774957,0.001054105,0.003214517],"category_scores_gemma":[0.001188823,0.0005595658,0.002288289,0.0003829939,0.0007071674,0.001169488,0.0004683823,0.00359199,0.0008239768],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001551376,"about_ca_system_score_gemma":0.002030885,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003193847,"about_ca_topic_score_gemma":0.009615285,"domain_scores_codex":[0.999415,0.0002661621,0.0000250079,0.00009290303,0.00006176118,0.0001392276],"domain_scores_gemma":[0.9994299,0.00008919316,0.0001083146,0.00005339602,0.00003728311,0.000281899],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8708204,0.02632403,0.00652032,0.0007576341,0.003831299,0.0001546512,0.000224387,0.00219456,0.01069987,0.0003367102,0.005600572,0.07253548],"study_design_scores_gemma":[0.7083957,0.258409,0.02231371,0.0001023169,0.001976205,0.0001770902,0.0001199307,0.001060413,0.001746903,0.000384122,0.00526452,0.00005002911],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9892337,0.002617585,0.00042436,0.0006047274,0.0002212647,0.001840502,0.002100777,0.00007037874,0.002886724],"genre_scores_gemma":[0.9839356,0.002955096,0.00146582,0.001410541,0.0002257317,0.001616491,0.004689147,0.00004091749,0.003660589],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003214517,"threshold_uncertainty_score":0.01125604,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04024679531211643,"score_gpt":0.3976870605521131,"score_spread":0.3574402652399966,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}